Local manufacturer Fabupharm says it can make Paracetamol tablets for the local market
Local manufacturer, Fabupharm this week announced that it is awaiting registration of its product dossier from the Namibian Medicines Regulatory Council (NMRC).
The company in a statement said the product screening has been approved and an expedition fee has been paid in an attempt to expedite the process.
Further to this, Fabupharm already has a paracetamol product registered with the NMRC, Fabu-Paracetamol syrup, which is being supplied to the Central Medical stores.
According to the company getting the product approved holds not only health, but also socio-economic benefits for the country.
“Namibians will have access to an affordable quality paracetamol product, manufactured in accordance with Good Manufacturing or GMP regulations as set out by the World Health Organization, the FDA and European Union,” they said.
Meanwhile, the local manufacturing of the products will mean increased employment opportunities for the residents of Otjiwarongo, where the factory is situated.
“The factory set-up comprises of a fully-equipped laboratory, a liquid filling line, tablet and capsule manufacturing equipment, industrial mixers, a reverse-osmosis water distillation plant, packaging and labelling equipment and the optimization of the plant and equipment is expected to increase by 10% if Fabupharm could supply the local market,” they added.
Fabupharm manufactures around 330 products and in addition to other registered products,the company also produces a range of non-registered complementary products such as vitamins and mineral supplements – the MVA and Suplimax ranges, VITA-KIDS syrup or drops and Oryl Hydration salts.
Fabupharm is 100% Namibian owned. In 2016, the Allegrow Fund, an SME and mid-market growth and operational development private equity fund focused solely on Namibia, purchased a 35% shareholding in Fabupharm.